Skip to Main Content

Chapter 92. Prostate Cancer

Which of the following is true regarding finasteride and dutasteride in the prevention of prostate cancer?

A. Dutasteride is FDA approved for prostate cancer chemoprevention.

B. Finasteride is FDA approved for prostate cancer chemoprevention.

C. Both finasteride and dutasteride are FDA approved for prostate cancer chemoprevention.

D. Neither agent is FDA approved, but the benefits and risks should be discussed with men with a normal PSA result and undergoing regular screening.

E. Neither agent is FDA approved and should not be used.

Which of the following does not increase the risk for prostate cancer?

A. African American ancestry

B. Older age

C. Benign prostatic hyperplasia

D. High-fat diet

E. Family history

Which of the following is the gold standard method for diagnosing prostate cancer?

A. Transrectal ultrasound (TRUS)

B. Digital rectal examination (DRE)

C. Prostate tissue biopsy

D. Prostate-specific antigen (PSA)

E. Bone marrow biopsy

Seizures are a rare, but serious adverse effect caused by which of the following medications?

A. Abiraterone

B. Enzalutamide

C. Docetaxel

D. Sipuleucel-T

E. Cabazitaxel

Which of the following is an effective method to decrease the tumor flare syndrome associated with the first few weeks of LHRH agonist therapy?

A. Start the LHRH agonist with a loading dose to rapidly achieve steady-state levels.

B. Start an antiandrogen before the LHRH agonist and continue for the first 3 to 4 weeks of therapy.

C. Start the LHRH agonist with a 50% dose decrease, slowly titrating to a full dose over 3 to 4 weeks.

D. Alternate LHRH agonists during the first 3 to 4 months of therapy.

E. Maintain testosterone levels above castration levels.

A 64-year-old man with newly ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.